ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Adalimumab"

  • Abstract Number: 2504 • 2016 ACR/ARHP Annual Meeting

    Impaired Vasodilator Function in Rheumatoid Arthritis Patients Who Flared Due to Stopping Adalimumab or Etanercept

    Gerard A Rongen1, Iris van Ingen2 and Tim L Jansen3,4, 1Internal Medicine/Pharmacology and Toxicology, Radboud UMC, Nijmegen, Netherlands, 2Rheumatology, RadboudUMC, Nijmegen, Netherlands, 3Rheumatology, VieCuri Medical Centre, Venlo, Netherlands, 4Scientific IQ HealthCare, Radboud UMC, Nijmegen, Netherlands

    Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) is associated with an increased cardiovascular risk, possibly due to disrupted vascular vasodilation. Within 12 weeks adalimumab and…
  • Abstract Number: 63 • 2016 ACR/ARHP Annual Meeting

    Identification of Immune Gene Modules in Good Responders to Adalimumab in Rheumatoid Arthritis

    James OIiver1, Darren Plant2, Gisela Orozco1, Samantha Smith1, Kimme L. Hyrich3, Ann Morgan4, John Isaacs5, Anthony G. Wilson6 and Anne Barton1,2, 1Arthritis Research UK, Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, 2NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust, Manchester, United Kingdom, 3Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, 5Institute of Cellular Medicine, Newcastle University and National Institute for Health Research Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, 6UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland

    Background/Purpose: Despite the revolutionary impact of TNF inhibitor (TNFi) therapy in rheumatoid arthritis (RA), up to 40% of patients fail to respond adequately. Whilst non-responder…
  • Abstract Number: 698 • 2016 ACR/ARHP Annual Meeting

    Performance of Modified Minimal Disease Activity (MDA) in Patients with Peripheral Spondyloarthritis

    Laura C. Coates1, Sonya Abraham2, William Tillett3, Philip J Mease4, Sofia Ramiro5, Yinglin Xia6, Xin Wang7, Aileen L. Pangan7 and In-Ho Song7, 1University of Leeds, Leeds, United Kingdom, 2NIHR/Wellcome CRF, Imperial College Healthcare NHS Trust, London, United Kingdom, 3Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 4Swedish Medical Center and University of Washington, Seattle, WA, 5Leiden University Medical Center, Leiden, Netherlands, 6University of Illinois at Chicago, Chicago, IL, 7AbbVie Inc., North Chicago, IL

    Background/Purpose: Due to lack of validated outcome measures in non-psoriatic peripheral spondyloarthritis (pSpA), recent studies in this patient (pt) population have used varying endpoints [1].…
  • Abstract Number: 2526 • 2016 ACR/ARHP Annual Meeting

    TNF Blocker Concentrations or Detection of Antibodies Against Anti-TNF before a Tapering Process Are Not Predictive to Relapse

    Hubert Marotte1,2, Mélanie Rinaudo-Gaujous3, Stéphane Paul3,4 and Bruno Fautrel5, 1SAINBIOSE INSERM U1059 and Rheumatology department, University of Lyon and University Hospital of Saint Etienne, Saint Etienne, France, 2Rheumatology Department, University Hospital of Saint-Etienne, Saint-Etienne, France, 3Laboratory of Immunology and immunomonitoring, CIC CIE3 Inserm Vaccinology, GIMAP EA3064, Hôpital Nord, Saint-Etienne, France, 4Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France, 5Rheumatology, Pitié Salpêtrière Hospital, Paris, France

    Background/Purpose:  The goal of rheumatoid arthritis (RA) strategy is to reach remission or at least a low disease activity. When this goal is reached, no…
  • Abstract Number: 80 • 2016 ACR/ARHP Annual Meeting

    Impact of a Patient Support Program on Abandonment of Adalimumab Treatment Initiation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis

    Philip Mease1, Manish Mittal2, Martha Skup2, Matthew Davis3, Arijit Ganguli2, Scott Johnson3 and Michael Schiff4, 1Swedish Medical Center and University of Washington, Seattle, WA, 2AbbVie Inc., North Chicago, IL, 3Medicus Economics, LLC, Milton, MA, 4University of Colorado, Greenwood Village, CO

    Background/Purpose: Treatment abandonment (failure to start therapy after prescription) is common among patients (pts) prescribed specialty pharmaceuticals. AbbVie offers a pt support program (PSP) for…
  • Abstract Number: 700 • 2016 ACR/ARHP Annual Meeting

    Incidence of Inflammatory Bowel Disease Events in Adalimumab (HUMIRA) Clinical Trials Across Indications

    Jeffrey R. Curtis1, Dirk Elewaut2, Su Chen3, Maja Hojnik4, Navit Naveh5 and Jaclyn K. Anderson3, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2VIB Inflammation Research Center, University of Ghent, Ghent, Belgium, 3AbbVie Inc., North Chicago, IL, 4AbbVie, Ljubljana, Slovenia, 5AbbVie, Hod HaSharon, Israel

    Background/Purpose:  Adalimumab (ADA) is approved for treatment of Crohn’s disease (CD) and ulcerative colitis (UC); therefore, it is postulated that new onset or flare of…
  • Abstract Number: 2531 • 2016 ACR/ARHP Annual Meeting

    Impact of Participation in the Adalimumab (Humira) Patient Support Program on Functional and Clinical Outcomes Among Patients with Rheumatoid Arthritis: Passion Study

    Filip van Den Bosch1, Andrew Östör2, Siegfried Wassenberg3, Jaclyn K. Anderson4, Naijun Chen5, Chen Wang4, Vishvas Garg5 and Jasmina Kalabic6, 1Rheumatology, Ghent University Hospital, Gent, Belgium, 2Addenbrooke's Hospital, Cambridge, United Kingdom, 3Rheumazentrum, Ratingen, Germany, 4AbbVie Inc., North Chicago, IL, 5AbbVie Inc, North Chicago, IL, 6AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

    Background/Purpose: Patients (pt) with Rheumatoid arthritis (RA) who are treated with  adalimumab (ADA) are offered a Patient Support Program (PSP) with variety of services. To…
  • Abstract Number: 84 • 2016 ACR/ARHP Annual Meeting

    Treatment Outcomes and Predictors of Patient Support Program Use Among Patients with Rheumatoid Arthritis: Results from a Post-Marketing Observational Study (PMOS)

    Filip van Den Bosch1, Siegfried Wassenberg2, Andrew Östör3, Chen Wang4, Jasmina Kalabic5 and Vishvas Garg4, 1Rheumatology, Ghent University Hospital, Gent, Belgium, 2Rheumazentrum, Ratingen, Germany, 3Addenbrooke's Hospital, Cambridge, United Kingdom, 4AbbVie Inc, North Chicago, IL, 5AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

    Background/Purpose: Patient (pt) support programs (PSPs) are offered to Rheumatoid arthritis (RA) pts to help manage treatment of this chronic disease. Little information is available…
  • Abstract Number: 701 • 2016 ACR/ARHP Annual Meeting

    In Patients with Ankylosing Spondylitis Treated with Adalimumab, Combination Therapy with DMARD, Increase the Serum Level of Adalimumab and Decrease Immunogenicity

    José Rosas1, Francisca Llinares-Tello2, José Miguel Senabre-Gallego1, Mariana Marco-Mingot3, Ana Pons1, Xavier Barber4, Gregorio Santos-Soler1, Esteban Salas-Heredia1, Catalina Cano1, Juan Molina3, Marina Sanchís4, Mario García-Carrasco5 and AIRE-MB Group, 1Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, 2Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, 3Laboratory, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, 4CIO, Universidad Miguel Hernández, Elche, Spain, 5Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico

    Background/Purpose: In patients with rheumatoid arthritis, methotrexate (MTX), improves the clinical efficacy of anti-TNF (TNFi), among other reasons, for reducing the immunogenicity. However, there are…
  • Abstract Number: 2601 • 2016 ACR/ARHP Annual Meeting

    A Cytometric Assay for Monitoring Adalimumab Immunogenicity and Drug Concentrations Can Distinguish Anti-Adalimumab Antibodies from Interference

    Morgan Casal1, Manda Ramsey1, Larry W. Moreland2 and Christian Fernandez1, 1Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, 2Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose:  Tumor necrosis factor inhibitor (TNFi) biologics are a mainstay of therapy for rheumatoid arthritis (RA) patients with disease-modifying antirheumatic drug failure. However, RA patients…
  • Abstract Number: 92 • 2016 ACR/ARHP Annual Meeting

    Is Patient Support Program (PSP) Participation Associated with Longer Persistence and Greater Adherence Among New Users of Adalimumab?

    Einav Srulovici1,2, Vishvas Garg3, Adi Ghilai2, Becca Feldman2, Moshe Hoshen2, Ran Balicer2, Martha Skup4 and Maya Leventer-Roberts2, 1School of Nursing, University of Haifa, Haifa, Israel, 2Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel, 3AbbVie Inc, North Chicago, IL, 4AbbVie Inc., North Chicago, IL

    Background/Purpose: In Israel, patients treated with adalimumab (ADA) can enroll in a patient support program (PSP) provided by AbbVie, which includes a home visit by…
  • Abstract Number: 735 • 2016 ACR/ARHP Annual Meeting

    Impact of Time Since Diagnosis, Age, and Number of Prior Non-Steroidal Anti-Inflammatory Drugs on Response to Adalimumab (HUMIRA) in Patients with Ankylosing Spondylitis

    Joachim Sieper1, Atul A. Deodhar2, Maja Hojnik3, Ying Zhang4 and Maxime Dougados5, 1Charité Universitätsmedizin Berlin, Berlin, Germany, 2Oregon Health and Science University, Portland, OR, 3AbbVie, Ljubljana, Slovenia, 4AbbVie, North Chicago, IL, 5René Descartes University and Hôpital Cochin, Paris, France

    Background/Purpose:  Ankylosing spondylitis (AS) patients (pts) were found to respond better to TNF inhibitors (TNFi) if treated early in the disease course. The objective of…
  • Abstract Number: 2638 • 2016 ACR/ARHP Annual Meeting

    In Vitro Expansion of Treg By Adaimumab Predicts Clinical Response to Therapy in Patients with Rheumatoid Arthritis

    Dao Xuan Nguyen, Centre of Rheumatology, Division of Medicine, University College London, London, United Kingdom

    Background/Purpose: Regulatory T cells (Treg) are potent suppressors of immune responses and are considered a pivotal element in resolving inflammation and autoimmunity. We have previously…
  • Abstract Number: 100 • 2016 ACR/ARHP Annual Meeting

    Patient Support Program for Adalimumab-Treated Patients in Brazil: Impact on Patients’ Adherence and Persistence

    Roger A. Levy1, Vanessa Teich2, Roberta Fernandes2, Anna Gulart2, Leonardo Chaves3, Vishvas Garg4 and Martha Skup5, 1Rheumatology, Department of Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 2Sense Company, São Paulo, Brazil, 3AbbVie Inc., Chicago, IL, 4AbbVie Inc, North Chicago, IL, 5AbbVie Inc., North Chicago, IL

    Background/Purpose: The Brazilian public healthcare system covers treatment with adalimumab for rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriatic arthritis, in line with local guidelines.…
  • Abstract Number: 1101 • 2016 ACR/ARHP Annual Meeting

    Adalimumab:TNF Complexes Induce a Divergent Proteomic Profile in Human Osteoclast Precursors to That Resembling a Monocytic Cell

    Bohdan P. Harvey1, Chenqi Hu2, Dongdong Wang2, Yu Tian2 and Zehra Kaymakcalan1, 1Global Biologics, AbbVie Bioresearch Center, Worcester, MA, 2DMPK-BA, AbbVie Bioresearch Center, Worcester, MA

    Background/Purpose:  TNF has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast (OC) development.…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 17
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology